Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Aug
16
Today In Oncology
What Is the Optimal PSA to Determine Prostate Cancer Treatment Efficacy
Can Newborn Genetic Testing Identify Cancer Predisposition Genes
FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma
Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
QOL Impact of Postmastectomy Chest Wall Radiotherapy 5-Year Follow-up
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo